Physician profile
Eliot J Greenberg
NPI 1710929989
$83,852.16
in general payments reported to CMS, 2019-2025
64 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $702 · 2021: $1,522 · 2022: $2,571 · 2023: $26K · 2024: $40K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Consulting Fee: $13K · Travel and Lodging: $9,423 · Food and Beverage: $5,852 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,070.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,407.50 |
| Consulting Fee | $13,135.50 |
| Travel and Lodging | $9,423.41 |
| Food and Beverage | $5,852.24 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55,768.26 | 2019-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13,319.90 | 2024-2025 | |
| Corium, LLC | $6,598.20 | 2022-2023 | Adlarity |
| Novartis Pharmaceuticals Corporation | $1,304.85 | 2019-2025 | |
| Abbvie INC. | $966.38 | 2021-2025 | |
| Biogen, INC. | $447.47 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Lilly USA, LLC | $399.94 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $393.57 | 2020-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $291.16 | 2020-2022 | |
| Neurelis, INC. | $287.26 | 2021-2025 | Valtoco |
| Ucb, INC. | $253.78 | 2019-2025 | Briviact, Fintepla |
| Genentech USA, INC. | $245.72 | 2019-2022 | |
| Emd Serono, INC. | $229.67 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $212.23 | 2019-2020 | |
| Sk Life Science, INC. | $198.25 | 2020-2024 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliot Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.